Loading viewer...
investor_presentation
Format: PDF investor_presentation
© 2020 Tonix Pharmaceuticals Holding Corp.1 November 2020 Version P0256 11-16-20 (Doc 0733)Investor Presentation NASDAQ:TNXP
© 2020 Tonix Pharmaceuticals Holding Corp.1
Version P0256 11-16-20 (Doc 0733)Investor Presentation
© 2020 Tonix Pharmaceuticals Holding Corp.2Cautionary Note on Forward -Looking
Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture
operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform
Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”
“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on
Tonix’s current expectations andactual results could differ materially .There areanumber offactors that
could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These
factors include, butarenotlimited to,risks related tofailure toobtain U.S.Food andDrug Administration
clearances orapprovals andnoncompliance withitsregulations ;ourneed foradditional financing ;delays and
uncertainties caused bytheglobal COVID -19pandemic; substantial competition ;uncertainties ofpatent
protection andlitigation ;uncertainties ofgovernment orthird party payor reimbursement ;limited research
anddevelopment efforts anddependence upon third parties .Aswithanypharmaceutical under development,
there aresignificant risks inthedevelopment, regulatory approval andcommercialization ofnewproducts .
Theforward -looking statements inthispresentation aremade asofthedate ofthispresentation, even if
subsequently made available byTonix onitswebsite orotherwise .Tonix does notundertake anobligation to
update orrevise anyforward -looking statement, except asrequired bylaw.Investors should read therisk
factors setforth intheAnnual Report onForm 10-Kfortheyearended December 31,2019,asfiledwiththe
Securities andExchange Commission (the“SEC”) onMarch 24,2020, andperiodic reports andcurrent reports
filed with theSEConorafter thedate thereof .AllofTonix's forward -looking statements areexpressly
qualified byallsuch riskfactors andother cautionary statements .© 2020 Tonix Pharmaceuticals Holding Corp.3Tonix Pharmaceuticals
© 2020 Tonix Pharmaceuticals Holding Corp.•Clinical-stage biopharmaceutical company
•Committed to discovering and developing innovative and
proprietary new therapeutics
•Focus on developing biologics and small molecules
•Vaccines, organ transplantation, oncology, autoimmune
•Central Nervous System (CNS)
•Pain, neurology, psychiatry, addiction© 2020 Tonix Pharmaceuticals Holding Corp.4Our Pipeline –Immunology & Biodefense
CANDIDATES INDICATION STATUS
Preview truncated — download the full document for the complete content.
investor_presentation
48 Pages
investor_presentation
63 Pages
ATCO Ltd.
Merdeka Copper Gold 2023 CITIC CLSA Investors Forum
investor_presentationinvestor_presentation
33 Pages
PT Merdeka Copper Gold Tbk
Bespoke Model Stock Portfolio December 2016
investor_presentationinvestor_presentation
4 Pages
Bespoke Investment Group